Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWarpaint London Regulatory News (W7L)

Share Price Information for Warpaint London (W7L)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 485.00
Bid: 480.00
Ask: 490.00
Change: -5.00 (-1.02%)
Spread: 10.00 (2.083%)
Open: 495.00
High: 500.00
Low: 485.00
Prev. Close: 490.00
W7L Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission to AIM & First Day of Dealings

30 Nov 2016 07:00

RNS Number : 4869Q
Warpaint London PLC
30 November 2016
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW

30 November 2016

Warpaint London plc

("Warpaint London" or the "Company")

Admission to Trading on AIM and First Day of Dealings

Warpaint London plc (AIM: W7L), a specialist supplier of colour cosmetics and owner of the W7 brand, is pleased to announce the admission today of its ordinary shares to trading on the AIM Market of the London Stock Exchange ("Admission"). Dealings in the ordinary shares will commence at 8.00am under the ticker "W7L" with the ISIN GB00BYMF3676.

Stockdale Securities Limited is acting as Nominated Adviser and Broker to the Company.

· Oversubscribed placing by Stockdale Securities Limited raising gross proceeds of £23 million

· 23,711,340 new and existing ordinary shares placed with institutional and other investors, including Board Directors (the "Placing"), at a placing price of 97 pence per ordinary share (the "Placing Price")

· The number of ordinary shares in issue immediately after Admission will be 64,538,600, giving Warpaint London a market capitalisation of approximately £62.6 million at the Placing Price

The Directors believe that the Admission to AIM will raise the Company's profile, enhance W7's brand awareness and provide investment to accelerate the growth of the business, as described in the Admission Document.

The Admission Document and details of significant shareholdings can be found at: www.warpaintlondonplc.com 

Sammy Bazini and Eoin Macleod, Joint CEOs of Warpaint London, commented: "Today marks a key milestone in the Company's 24-year history. The public company status will greatly support our expansion as we continue to broaden W7's customer base internationally, introduce additional brands and product lines and generate further profitable growth.

 

"The support from investors who recognise the exciting opportunities of the growing and global cosmetics market has been very encouraging. We are very much looking forward to our life as a public company and are excited to update our investors on the continued progress of the business in the months and years to come."

 

Company Overview

· Warpaint London is a well-established business originally founded in 1992, that sells colour cosmetics in the UK and internationally, principally under the W7 brand

 

· The flagship W7 brand has seen consistent growth and has more than 230 customers in over 40 countries

o W7 was the prefix of the Company's postcode in West London at the time of the brands' inception in 2002

o W7 is an extremely creative, design-focussed cosmetic brand delivering high-quality colour cosmetics at affordable prices, targeting the 16-30 age range.

o The own-brand division has four other brands which have, to date, been relatively undeveloped

 

· Strategy for growth is focused on the own-brand proposition

 

· The Company has a proven track record of sales growth, profitability and strong cash generation

o Revenue increased in FY2015 to £22.3 million (FY2014: £17 million) and EBITDA increased to £5.5 million (FY2015: £4.2 million), driven primarily by growth in awareness of the W7 brand

o Strong current trading, with H1 2016 revenue increasing to £12.7 million (H1 2015: £10.8 million), and H1 2016 EBITDA increasing to £3.3 million (H1 2015: £2.6 million)

o Robust balance sheet with £11.4 million of net assets as at 30 June 2016 and highly cash generative

 

· Intention to adopt a progressive dividend policy

 

· The cosmetics market is believed by the directors of the Company to be an attractive growth market which is made up of two categories; prestige and mass

o The accessible price points of the mass market see consumers buying from these brands more frequently

o The US is the largest colour cosmetics market globally with a retail value in 2015 of approximately $11 billion. The UK colour cosmetics market is estimated to grow from £1.8 billion in 2016 to c.£2.4 billion in 2021

 

· The management team has over 70 years' combined experience in the cosmetics industry and the Company has a highly experienced board

 

Enquiries:

Warpaint London plc

Sammy Bazini - Joint Chief Executive

Eoin Macleod - Joint Chief Executive

Neil Rodol - Chief Financial Officer

 

020 3053 8671

 

Stockdale Securities Limited (Nominated Adviser and Broker)

Andy Crossley, Antonio Bossi, Ed Thomas - Corporate Finance

Fiona Conroy - Corporate Broking

 

020 7601 6100

 

IFC Advisory (Financial PR & IR)

Tim Metcalfe

Graham Herring

Heather Armstrong

Miles Nolan

020 3053 8671

 

 

About Warpaint London plc

Warpaint London is a colour cosmetics business, based in Iver, Buckinghamshire. It is made up of two divisions: close-out and own-brand. The second and larger own-brand division consists primarily of the Group's flagship brand, W7 - an extremely creative, design-focussed cosmetic brand proposition with a focus on the 16-30 age range, delivering high-quality cosmetics at affordable prices. W7 brand has grown organically since its inception in 2002 and now contains over 500 items which are sold into high street retailers and independent beauty shops across the UK, Europe, Australia and the US. In 2015, W7 was supplied to over 230 customers in more than 40 countries.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEADFNASLKFAF
Date   Source Headline
24th Apr 20247:00 amRNSResults for the year ended 31 December 2023
9th Apr 20247:00 amRNSBlock listing Interim Return
9th Apr 20247:00 amRNSTrading Update and Notice of Results
26th Mar 20242:37 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSWard & Hagon Contract Renewal
12th Jan 20247:00 amRNSTrading Update
12th Dec 20237:00 amRNSAppointment of Non-Executive Directors
1st Dec 20233:37 pmRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of Options
21st Nov 202311:23 amRNSPDMR Dealing
20th Nov 20231:24 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSTrading Update
9th Nov 20237:00 amRNSBlock Listing Interim Return
31st Oct 20237:00 amRNSTotal Voting Rights
13th Oct 20233:38 pmRNSHolding(s) in Company
4th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20233:26 pmRNSHolding(s) in Company
3rd Oct 202312:25 pmRNSBlocklisting Application
28th Sep 20235:47 pmRNSHolding(s) in Company
20th Sep 20237:00 amRNSInterim Results
19th Sep 20233:51 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
22nd Aug 202312:31 pmRNSHolding(s) in Company
27th Jul 20234:34 pmRNSHolding(s) in Company
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20231:40 pmRNSResult of AGM
28th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSTrading Update
6th Jun 20237:00 amRNSPDMR Dealings
24th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
9th May 202311:28 amRNSHolding(s) in Company
2nd May 20234:31 pmRNSBlocklisting Application
26th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Mar 20237:00 amRNSTrading Update and Notice of Results
14th Feb 202310:16 amRNSAIM Rule 17 Notification
11th Jan 20237:00 amRNSFull Year Trading Update
3rd Jan 20237:00 amRNSResignation of Non-Executive Director
14th Oct 20227:00 amRNSRenewal of New Moorcroft House lease at Silsden
21st Sep 20227:00 amRNSInterim Results
16th Sep 20227:00 amRNSChange of Adviser
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20222:06 pmRNSSecond Price Monitoring Extn
8th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 202211:05 amRNSSecond Price Monitoring Extn
8th Sep 202211:00 amRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSTrading Update
1st Sep 20227:00 amRNSNotice of Results and Investor Webinar
29th Jun 20227:00 amRNSPMDR / PCA Dealing
28th Jun 20227:00 amRNSDirector/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.